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The hepatitis C virus NS3 proteinase plays an essential role in processing of HCV nonstructural precursor polyprotein. To
detect its processing activity, we developed a simple trans-cleavage assay. Two recombinant plasmids expressing the NS3
proteinase region and a chimeric substrate polyprotein containing the NS5A/5B cleavage site between maltose binding
protein and protein A were co-introduced into Escherichia coli cells. The proteinase processed the substrate at the single
site during their polyprotein expression. Deletion analysis indicated that the functionally minimal domain of the NS3
proteinase was composed of 146 amino acids, 1059 to 1204. We isolated several cDNA clones encoding the functional
domain of the NS3 proteinase from the sera of patients chronically infected with HCV and determined their proteinase activity
by this trans-cleavage assay. Both active and inactive clones existed in the same patients. Comparative sequence analyses
of these clones suggested that certain point mutations seemed to be related to the loss of proteolytic activity. This was
confirmed by back mutation experiments. Among the critical mutations, Pro-1168 to Thr and Arg-1135 to Gly were intriguing.
These amino acids, which are situated near the oxyanion hole, seem to be essential for maintaining the conformation of the
active center of the NS3 proteinase. © 1998 Academic Press
INTRODUCTION
Hepatitis C virus (HCV) is the major etiological agent
of posttransfusion non-A, non-B hepatitis worldwide
(Choo et al., 1989; Kuo et al., 1989). HCV infection results
in mild and acute liver disease, but chronic infections are
common and may eventually develop into cirrhosis or
hepatocellular carcinoma (Saito et al., 1990). Although
interferons are currently used for the treatment of chronic
hepatitis, their efficacy is limited to a small portion of
patients owing to insufficient suppression of HCV repli-
cation. Therefore, another reliable anti-HCV agent is nec-
essary to control HCV hepatitis.
HCV has positive-strand RNA approximately 9400 nu-
cleotides long which encodes a single polyprotein of
about 3010 amino acids (aa) (Choo et al., 1989, 1991; Kato
et al., 1990; Takamizawa et al., 1991). Since its genomic
organization is similar to those of flaviviruses and pesti-
viruses, HCV is classified as a member of the family
Flaviviridae (Miller and Purcell, 1990; Takeuchi et al.,
1990). Following the 59-untranslated region, the viral
structural proteins are located at the amino (N)-terminal
region of the polyprotein in the order of core, E1 and E2.
After being translated as a precursor polyprotein, the
structural proteins are processed by a host cell signal
peptidase(s), perhaps with no apparent involvement of
virus-coded proteinase. The nonstructural (NS) proteins,
which represent the essential machinery for viral repli-
cation, are located in the carboxyl (C)-terminal region in
the order of NS2-NS3-NS4A-NS4B-NS5A-NS5B (Rice,
1996). In contrast to the cleavage of the structural pro-
teins by the host enzyme, the NS proteins are processed
by virus-coded proteinases. The HCV has two protein-
ases, NS2/3 proteinase and NS3 serine proteinase. The
cleavage at NS2-NS3 is mediated by the former protein-
ase encoded within a region composed of the C-terminal
portion of the NS2 gene and the N-terminal portion of the
NS3 gene. Most likely this enzyme is a zinc-dependent
metalloproteinase whose His-952 and Cys-993 were in-
volved in catalysis (Grakoui et al., 1993a; Hijikata et al.,
1993a). This putative metalloproteinase partially overlaps
with the NS3 serine proteinase and presumably auto-
cleaves the NS2/NS3 junction. The NS3 serine protein-
ase was shown to cleave the NS3/NS4A, NS4A/NS4B,
NS4B/NS5A, and NS5A/NS5B junctions (Manabe et al.,
1994). The active site of this proteinase is composed of
three highly conserved aa residues, His-1083, Asp-1107,
and Ser-1165, which are well known as a catalytic triad of
the serine proteinase family (Bazen and Fletterick, 1990;
Bartenschlager et al., 1993). It was confirmed that the
Ser-1165 in the NS3 protein was essential for cleaving
the downstream portion of the polyprotein by using in
vitro transcription–translation systems and some mam-
malian cell culture systems (Chambers et al., 1990; Gra-
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koui et al., 1993b,c; Hijikata et al., 1993b; Tomei et al.,
1993). Comparison of the sequences around each cleav-
age site revealed the unique substrate specificity of the
proteinase: Cys or Thr at the P1 position, Ser or Ala at the
P19 position, and Asp or Glu at the P6 position (Grakoui
et al., 1993b). Among other NS proteins, NS4A, a 54-
residue amphipathic peptide, was shown to act as a
cofactor for the NS3 proteinase interacting with the N-
terminal portion of the enzyme (Bartenschlager et al.,
1995). Recently, the crystal structures of NS3 serine pro-
teinase were reported from two groups. The tertiary
structure of the proteinase was revealed to adopt a
chymotrypsin-like folding, and its unique conformational
aspects including a zinc-binding site and its complex
formation with an NS4A peptide were elucidated (Kim et
al., 1996; Love et al., 1996).
Since the viral serine proteinase is an attractive target
for antiviral therapy, several assay systems of NS3 pro-
teinase using in vitro transcription–translation systems
and some mammalian cell culture systems have already
been developed. Previously, we constructed an enzy-
matic assay system using one of our original HCV
clones, D51, which displays functional activity of the
purified enzyme in vitro, and studied the characteristics
of the proteinase (Mori et al., 1996). We also reported the
importance of the N-terminal part of NS3 for its protein-
ase activity (Mori et al., 1997). In parallel with these
previous studies, we newly cloned HCV proteinase
genes from HCV-positive sera of chronic hepatitis pa-
tients into a plasmid of Escherichia coli and examined
their ability to cleave a coexpressed substrate fusion
protein containing the NS5A/5B cleavage site between
maltose binding protein (MBP) and protein A. It was
found that the isolated NS3 proteinase clones had vari-
ety of activities and some of them were inactive. In this
study, we identified critical point mutations at Pro-1168
and Arg-1135, which lead to loss of proteinase activity,
and discuss how these amino acids contribute to the
processing activity from a structural point of view.
RESULTS
Construction of trans-cleavage assay system
in E. coli
To evaluate the activity of isolated HCV NS3 protein-
ase clones, we developed an assay system which de-
tects the proteinase activity by cotransformation of E. coli
with expression plasmids containing a cloned NS3 pro-
FIG. 1. Construction of trans-cleavage assay system in E. coli. (A) Schematic representation of the recombinant substrates and the HCV NS3
proteinases produced by the expression plasmids. (B) A substrate (MCP-C2, lanes 1, 3, 5, 7, and 9; MCP-A1, lanes 2, 4, 6, 8, and 10) and an enzyme
clone (MKC3, lanes 1 and 2; MKC4, lanes 3 and 4; D51, lanes 5 and 6; D51S1165A, lanes 7 and 8; vector only, lanes 9 and 10) were coexpressed in
double transformants of the substrate and the enzyme expression vectors by IPTG induction. The proteolytic activity was analyzed by SDS–PAGE
followed by CBB staining. The substrate (68 kDa) and the products (43 and 29 kDa) are indicated by arrows. (C) Western blotting of the same sample
as (B) using HRP-conjugated goat IgG anti-rabbit IgG. Only the substrate and the processed C-terminal product (68 and 29 kDa), which contained a
protein A domain, were detected. The details are given under Materials and Methods.
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teinase and a recombinant substrate. First, our protein-
ase-active original cDNA clones pMKC3, pMKC4, and
pD51, which encode the residues 900–1260 of the viral
polyprotein, were introduced into E. coli together with
substrate expression plasmid pMCP-C2, which encodes
a fusion protein containing the NS5A/5B cleavage se-
quence between MBP and protein A junctions (Fig. 1A).
As shown in Fig. 1B, we found at the CBB staining level
that the substrate (68 kDa) was cleaved into two
polypeptides, MBP (43 kDa) and protein A (29 kDa). The
processing activity was confirmed by Western blotting
analysis using HRP-conjugated IgG (Fig. 1C). N-terminal
sequence analysis of the protein A band produced by the
proteinase revealed that the substrate was indeed pro-
cessed at the NS5A/5B cleavage site (data not shown).
When the Ser-1165 of the enzyme was replaced with Ala
(Figs. 1B and 1C, lanes 7) or the P1 Cys residue of the
recombinant substrate was replaced with Ala (Figs. 1B
and 1C, lanes 2, 4, 6, 8, and 10), the cleavage was not
observed. These results indicated that this assay is use-
ful for screening for functional cDNA clones with protein-
ase activity.
Deletion analysis of the proteinase region
Using this E. coli trans-cleavage assay, we then deter-
mined the minimal region to maintain the proteinase
activity. A series of N- and C-terminal deletion mutants
from the D51 clone were constructed and subjected to
the trans-cleavage assay (Figs. 2A–2C). Although the
cleavages by the proteinase region (900–1260) and
(1059–1214) were not efficient for detection by CBB stain-
ing (Fig. 2B), they were clearly detected by Western
blotting (Fig. 2C). The N-terminal deletion experiments
(lanes 2, 5, 7–14) indicated that the N-terminal border
essential for trans cleavage of the substrate at the 5A/5B
site was Val-1059. On the other hand, the C-terminal
deletion experiments (lanes 2–6, 15) indicated that the
functional C-terminal border was Thr-1204. From these
results, the minimal NS3 proteinase region was nar-
rowed down to the region between aa residues 1059 and
1204. To detect the proteinase activity sensitively, we
adopted Western blotting analysis in the following exper-
iments.
cDNA cloning of NS3 proteinase region from a
patient and determination of its activity
Using RT–PCR methods, we isolated cDNA fragments
of the HCV genome coding NS3 proteinase region 1027–
1260 from two patients’ sera (N and U). From each serum,
we obtained several clones and examined them individ-
ually for their proteinase activity (Fig. 3). Several clones
did not cleave the substrate (Fig. 3, clones MKC2, N-A1,
FIG. 2. Mapping of the minimal NS3 region required for cleavage at the NS5A/NS5B site. A series of N- and C-terminal deletion mutants from D51
proteinase clone were constructed and subjected to the trans-cleavage assay. (A) Schematic representation of the deletion mutants used in the assay.
The numbers indicated on the left side correspond to the lane numbers in (B) and (C). (B) The processing activities of each deletion mutant were
determined by SDS–PAGE followed by CBB staining. (C) The substrate and the processed C-terminal product, which contained a protein A domain,
were detected by Western blotting using HRP-conjugated goat IgG anti-rabbit IgG.
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N-A3, and U-2). Since the expression of the NS3 enzyme
was detected in each assay sample except for clone
N-A1 (data not shown), the cDNA clones MKC2, N-A3,
and U-2 were considered not functional.
To study the correlation between their aa sequences
and their cleavage activities, we analyzed DNA se-
quences of each isolated clone. In the total nucleotide
sequences, 1.18 and 0.27% of base substitutions from the
consensus sequence were found in the clones derived
from sera N and U, respectively (data not shown). These
mutation rates account for 0.85% of the combined total
sequences. However, 85% of the substitutions occurred
at the third codon and aa changes were not frequent.
Figure 4 shows aa sequences of each clone. The se-
quences of clone N-B5, N-B6, N-B9, N-B11, and N-B13
were the same as that of N-A2, and the sequence of
N-B12 was the same as that of N-B3. Similarly, se-
quences of U-3, U-6, U-7, and U-11 were identical to that
of the U-1 clone. From the comparative alignment, it was
revealed that the sequences could be classified into two
groups by their serum source, N or U at six positions (at
1115, Pro and Ser; at 1148, Asn and Thr; at 1151, Ser and
Ala; at 1196, Val and Ile; at 1222, Ala and Thr; at 1239, Lys
and Arg, respectively). In addition to such diversity, each
clone had a few extra minor point mutations. However,
the majority of such minor mutations did not affect pro-
teinase activity (Fig. 3). Among four inactive clones, clone
N-A1 had a single base pair deletion which made a stop
codon at aa 1079 (Fig. 5A). The appearance of a stop
codon was consistent with the finding that the enzyme
expression was not detected in clone N-A1 (data not
shown). The aa sequence of its back mutant N-A1N,
instead of the sequence of N-A1, is shown in Fig. 4. The
other inactive clones, MKC2, N-A3, and U-2, had a re-
placement of Arg-1135 by Gly, Pro-1168 by Thr, and His-
1083 by Leu, respectively. These point mutations seemed
to cause the loss of activity of the NS3 enzyme.
Analysis of the inactive proteinase clones
The comparative alignment revealed that the aa se-
quence of clone U-2 was identical to that of clone U-1
except for His-1083. Therefore, it was concluded that the
loss of the proteinase activity was due to the point
mutation at His-1083 to Leu. Since His-1083 is one of the
catalytic triad residues (His-1083, Asp-1107, Ser-1165), it
was clear that the point mutation at this site caused the
loss of proteinase activity (Hijikata et al., 1993a).
To examine whether the aa substitutions in other in-
active clones caused the loss of activity, we next con-
structed a back mutant for each inactive clone. A corre-
sponding nucleotide was inserted to correct the non-
sense mutation in clone N-A1 and a single base pair
substitution was introduced in MKC2 and N-A3, respec-
tively (Fig. 5A). When the back mutant clones N-A1N,
MKC2N, and N-A3N were introduced in E. coli together
with the substrate expressing plasmid, cleavages of the
recombinant substrate were observed in all cases (Fig.
5B). These results confirmed that each predicted aa
change caused the loss of proteinase activity. The im-
munoblot analysis using anti-NS3 polyclonal antibody
showed that each enzyme, except for the clone N-A1,
normally expressed in E. coli (Fig. 5B, bottom), eliminat-
ing the possibility that the failure of detection of the
proteinase activity was due to the enzyme instability or
low-level expression. To further analyze the contribution
of positive charge at the side chain of position 1135 to
the processing activity, we prepared additional mutants
from clone D51, in which Arg-1135 was substituted by
Lys (D51R1135K) or Gln (D51R1135Q) as well as Gly
(D51R1135G). Interestingly, it was found that Gln as well
as Lys could substitute for Arg. However, when the res-
idue was changed to Gly, the D51 clone lost its activity,
like the MKC2 clone (Fig. 5B). This finding indicates that
any factor other than a positive charge at position 1135
may contribute to the NS3 proteinase activity. Further-
more, mobility shift of the enzyme was observed in the
mutants at position 1135, suggesting the importance of this
aa position for enzyme conformation (Fig. 5B, bottom).
FIG. 3. Determination of processing activities of NS3 proteinase
cDNA clones obtained from HCV-infected patients’ sera. HCV NS3
proteinase cDNAs encoding the aa sequence from 1027 to 1260 of the
HCV precursor polyprotein were cloned into the expression plasmid as
described under Materials and Methods. Each clone was coexpressed
with the substrate expression plasmid pMCP-C2 (Fig. 1A) in E. coli and
its processing activity was determined. Both precursor and processed
polyproteins containing a fused protein A domain were detected by
Western blotting with HRP-conjugated IgG. Clones N-A1–A4 and N-B1–
B14 were isolated from the serum of patient N. Also, clones U-1–11
were isolated from another sole serum source, patient U.
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DISCUSSION
We developed a trans-cleavage assay of HCV NS3
proteinase which detected its specific cleavage activity
in E. coli. By using a coexpressed proteineous substrate,
the cleavage activity was easily detected by SDS–PAGE
and Western blotting. Using this trans-cleavage assay,
we determined the minimal proteinase region in the
N-terminal third of the NS3 gene by constructing a series
of deletion mutants of the D51 clone. Previously, the
proteinase domain was identified within region 1049–
1215 (Tanji et al., 1994) and we also used the region
1050–1214 as an active NS3 proteinase for its character-
ization (Mori et al., 1996). In this study, the analyses of
additional deletion mutants revealed that the minimal
proteinase region was mapped between Val-1059 and
Thr-1204 of HCV precursor protein, which was con-
structed with 146 aa residues (Fig. 2). The tertiary struc-
ture of the proteinase was revealed to adopt a chymot-
rypsin-like folding (Kim et al., 1996; Love et al., 1996). It
was reported that positions of secondary structure ele-
ments were well matched to those of chymotrypsin, al-
though some b strands did not superimpose with the
equivalent strands in other chymotrypsin-like protein-
ases. Both the terminal residues of the minimal region,
Val-1059 and Thr-1204, are located at the N-terminal end
of b strand A1 and the end of C-terminal a helix, respec-
tively (Kim et al., 1996; Love et al., 1996). NS3(1059–1204)
covers the minimal region containing all secondary
structures which are conserved among chymotrypsin-
like proteinase family members. Our results suggest that
this region forms a core domain essential for processing
activity.
In the course of studying the activity of HCV proteinase
cDNA clones obtained from HCV-infected patients, we
found both functionally active and inactive clones of NS3
proteinase by the trans-cleavage assay (Fig. 3). It is
interesting that some inactive clones (N-A1, N-A3 from
serum N and U-2 from serum U) existed together with
FIG. 4. Comparative alignment of the deduced amino acid sequences of the NS3 proteinase genes. MKC3, MKC4, and N-A1–A4 were initially obtained
as 1196-bp DNA fragments encoding the aa sequence from 900 to 1260 of the HCV precursor polyprotein. The others were obtained as 716-bp DNA
fragments encoding the aa sequence from 1027 to 1260 of the HCV precursor polyprotein. Although MKC3 and MKC4 are identical within the NS3 region,
they are different within the NS2 region. The clones isolated from the same patient’s serum are indicated by brackets. N-A1N is a proteinase-positive
revertant of N-A1, which was mutated by a single base pair (G/C) insertion at the starred position (Fig. 5). Amino acid residues predicted to be null mutations
are indicated in bold capitals. The residues predicted to form a catalytic triad (H1083, D1107, and S1165) are indicated by #.
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active clones in the same patient’s serum. The sequenc-
ing analysis of the cloned NS3 genes revealed that the
base substitutions amounted to 0.85% in the total nucle-
otide sequences (data not shown). Among the substitu-
tions, 85% of the cases occurred at the third codon,
which did not change the aa sequences. Since the anal-
ysis of the sequence of HCV genome might inevitably
involve the possibility of nucleotide change due to PCR
error, we are not able to entirely exclude such possibility.
However, these biased nucleotide mutations may reflect
the characteristics of an error-prone RNA-dependent
RNA polymerase and the lack of an associated repair
mechanism in the viral replication, which may cause the
quasispecies of the HCV genome within infected individ-
uals (Bukh et al., 1995). Among such quasispecies, some
mutations may happen to change an aa residue(s) criti-
cal for proteinase activity. In this study, we identified four
cases of such critical mutations in sera of patients chron-
ically infected with HCV.
Among the four inactive clones, N-A1 was found to
have a nonsense mutation at position 1079 (Fig. 5A).
Since the translation of the HCV polyprotein may be
terminated at the stop codon, N-A1 is considered to be a
clone defective in HCV replication. In another inactive
clone, U-2, a point mutation occurred at a histidine res-
idue of the catalytic triad (His-1083) and directly made
the proteinase inactive. In the third case of N-A3, muta-
tion at Pro-1168 was revealed to induce inactivation of
the enzyme. The proline residue follows the ‘‘oxyanion-
stabilizing loop’’ (Leu-1161 to Ser-1165), which constitutes
an active center. It is possible that this proline residue is
structurally critical and its substitution for threonine dis-
torted the conformation of the main chain within the loop
and caused loss of the enzyme activity. In the fourth
inactive clone, MKC2, Arg-1135 was replaced by glycine,
which was located on a loop between b strands A2 and
B2 in the C-terminal domain and was positioned just
behind the oxyanion hole of the active center (Kim et al.,
1996; Love et al., 1996). The side chain at position 1135
may contribute to the processing activity by certain in-
teractions with amino acids constituting the ‘‘oxyanion-
stabilizing loop.’’ Since a glutamine residue could sub-
stitute for Arg-1135 as shown in Fig. 5B, a positive charge
at this position may not be very important for the inter-
actions. The volume of the side chain might be critical in
interactions such as hydrogen bonds, and the smallest
side chain of glycine might lead to loss of such interac-
tion causing the enzyme to be inactive in the clone
MKC2.
The trans-cleavage assay described here could be
used for analyses to measure the activity of NS3 protein-
ase clones and to identify quasispecies of the proteinase
FIG. 5. Mutation analysis of proteinase-defective clones. (A) Predicted mutation sites of proteinase-defective clones. Underlines indicate replaced
aa residues and nucleotides. (B) To confirm the predicted null mutation sites shown in (A), back mutation experiments were performed. The Opal
mutation (indicated as Op in the figure) in N-A1 was repaired by single G/C base pair insertion. The aa sequence of the resultant clone designated
as N-A1N is shown in Fig. 4. The Thr-1168 in N-A3 and the Gly-1135 in MKC2 were replaced by Pro (N-A3N) and Arg (MKC2N), respectively.
Furthermore, the Arg-1135 in D51 (an active clone) was replaced by Gly (D51R1135G), Lys (D51R1135K), or Gln (D51R1135Q) residues. D51S1165A, in
which the Ser-1165 was replaced by Ala residue, was used as inactive control. The proteinase activities of these clones were determined by
trans-cleavage assay in E. coli. The bottom part of this figure shows the expression of NS3 proteinase analyzed by Western blotting using rabbit
polyclonal anti-NS3 antibody.
109CRITICAL MUTATIONS FOR HCV NS3 PROTEINASE
sequences. The system would be also useful for reveal-
ing the amino acids critical in inactive HCV clones. Ac-
cumulation of such information should be helpful for
understanding the relationship between the structure
and the activity of the enzyme.
MATERIALS AND METHODS
Construction of substrate expression vectors
The expression plasmid pMCP1, which encodes E.
coli MBP and Staphylococcus aureus protein A in
tandem, is a derivative of pMAL-c2 (New England
BioLabs, Inc., MA) and pRIT2 (Pharmacia Biotech, Inc.,
Uppsala, Sweden). Plasmid pMCP1 also contains mul-
tiple cloning sites (HindIII to XbaI site of pUC19) be-
tween the MBP gene and the protein A gene. Sub-
strate expression plasmids, pMCP-C2 and pMCP-A1,
which encode fusion proteins containing appropriate
aa sequences around the NS3 proteinase cleavage
site between the MBP and protein A junctions (Fig.
1A), were constructed by inserting phosphorylated
linkers into the HindIII–XbaI site of pMCP1. The syn-
thetic oligonucleotide pairs used in these construc-
tions are as follows: for plasmid pMCP-C2, 59-AGCT-
TGGCGACGACATCGTCTGCTGCTCAATGTCCTACT-39
and 59-CTAGAGTAGGACATTGAGCAGCAGACGATGTC-
GTCGCCA-39; for plasmid pMCP-A1,59-AGCTTGGCGA-
CGACATCGTCTGCGCCTCAATGTCCTACT-39 and 59-CTAG-
AGTAGGACATTGAGGCGCAGACGATGTCGTCGCCA-39.
Cloning of NS3 proteinase genes
The expression plasmids pWNH71 and pWB298 each
contain a 13 N-terminal amino acid leader sequence
derived from a nitrile hydratase gene, which are driven
under the control of the trc promoter. This leader se-
quence possesses a consecutive stretch of histidine
(His) residues which allows the fusion protein to be
purified with ease in a single step by metal chelating
affinity chromatography.
HCV RNA molecules were purified from 50 ml of an
HCV patient’s serum (a gift from Dr. N. Hayashi) by using
RNAzol B (Tel-Test, Inc., Texas) and subjected to cDNA
synthesis, followed by the reverse transcription–poly-
merase chain reaction (RT–PCR). To amplify the NS3
region, the following oligonucleotides were used as
nested PCR primers: forward primers, YH351 (59-TTAA-
GCTTCTCGGTCCGCTCATGGTRCTCCARGC-39) and YH357
(59-TTAAGCTTGCGCCYATCACGGCCTAYTCCC-39); back-
ward primers, YH354 (59-TAAGATCTARGCRGCAACRGA-
IGGRAGGACG-39) and KY390 (59-TAGGATCCTARGCRG-
CAACRGAIGGRAGGACG-39) (Underlines denote the re-
striction sites used for subcloning, and nucleotides in
bold type indicate the stop codon.) To amplify the cDNA
fragment encoding aa residues 900 to 1260 in the HCV
polyprotein, a primer set of YH351 and YH354 was used.
To amplify the cDNA fragment encoding aa residues
1027 to 1260 in the HCV polyprotein, a primer set of
YH357 and KY390 was used.
The HindIII–BglII fragment and the HindIII–BamHI
fragment of the PCR products were ligated into the
HindIII–BglII site of pWNH71 and the HindIII–BamHI
site of pWB298, respectively. To screen enzymatically
active NS3 proteinase clones, as described later, the
ligated plasmid DNA and the substrate expression
plasmid pMCP-C2 were co-introduced into E. coli DH5
cells. Since the substrate and the enzyme expression
vectors have different replication origins and different
antibiotic-resistant markers, both plasmids can be
maintained under selective pressure. Ampicillin and
kanamycin double-resistant colonies were selected as
the transformants harboring the two plasmids, and the
plasmid DNAs were subjected to restriction endonu-
clease analysis.
Detection of NS3 proteinase activity in E. coli
expression system
Recombinant E. coli strains harboring the two plas-
mids were precultured overnight in LB broth (Difco) con-
taining ampicillin (50 mg/liter) and kanamycin (30 mg/
liter) at 30°C with shaking. The cultured cells were inoc-
ulated at 1/50 dilution into the same broth and incubated
further at 37°C. When the OD650 reached 0.8, isopro-
pyl-b-D-thiogalactopiranoside (IPTG) was added at the
final concentration of 0.5 mM, and the culture was further
incubated for 4 h. After the cultured cells were harvested
and suspended in 0.85% NaCl, a portion of the suspen-
sion was mixed with Laemmli’s sample buffer and ana-
lyzed by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS–PAGE).
SDS–PAGE was carried out in a 14% acrylamide slab
gel and the gel was stained with Coomassie brilliant blue
(CBB). In addition, Western blot analysis was carried out
after SDS–PAGE. The processed products from the C-
terminal region of the substrate protein, containing pro-
tein A-fused polypeptide, was detected with horseradish
peroxidase (HRP)-conjugated goat IgG anti-rabbit IgG. To
confirm the expression of the NS3 protein in E. coli cells,
rabbit anti-NS3 IgG prepared from a rabbit immunized
with purified recombinant protein (aa 900 to 1260; ex-
pressed in E. coli) was used as the first antibody, and
HRP-conjugated goat IgG anti-rabbit IgG as the second.
Mutagenesis
Site-specific mutagenesis was accomplished by using
a PCR-based method (Ho et al., 1989). All constructs
were confirmed by sequencing analysis. The PCR prim-
ers used were as follows: Vector primers; forward primer,
59-TGTGAGCGGATAACAATTTCGGATC-39, and backward
primer, 59-TCGGCCGCCCGACTATCACCGCCC-39; muta-
genesis primers; for MKC2 (G11353R): 59-CTTTACCTG-
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GTCACGAGACATGCTGATGTC-39 and 59-GACATCAGCA-
TGTCTCGTGACCAGGTAAAG-39; for N-A1 (amber 3
W1079; 1 G/C bp insertion): 59-AACGGCGTGTGTTGGAC-
TGTCTACCATGG-39 and 59-ACCATGGTAGACAGTCCAA-
CACACGCCGTT-39; for N-A3 (T1168 3 P): 59-GCTCTTC-
GGGTGGTCCGCTGCTTTGCC-39 and 59-GGCAAAGCAG-
CGGACCACCCGAAGAGC-39; for D51 (R1135 3 G): 59-
CTTTACTTGGTCACGGGACATGCTGATGTC-39 and 59-
GACATCAGCATGTCCCGTGACCAAGTAAAG-39; for D51
(R1135 3 K): 59-CTTTACTTGGTCACGAAACATGCTGAT-
GTC-39 and 59-GACATCAGCATGTTTCGTGACCAAGTA-
AAG-39; for D51 (R11353 Q): 59-CTTTACCTGGTCACGC-
AACATGCTGATGTC-39 and 59-GACATCAGCATGTTGCG-
TGACCAGGTAAAG-39; for D51 (S1165 3 A): 59-TGAAG-
GGTTCCTGCGGTGGTCC-39 and 59-GGACCACCGCAGG-
AACCCTTCA-39, forward and backward primers, respec-
tively.
Construction of deletion mutants
All deletion mutants were constructed by the PCR. The
HindIII–BglII fragment and the HindIII–BamHI fragment
of PCR products were ligated into the HindIII–BglII site of
pWNH71. All constructs were confirmed by sequencing
analysis.
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